| Methods |
2‐week washout; 2‐week single‐blind placebo run‐in; inclusion criteria= mean supine DBP 95‐114 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Trandolapril 2 mg: n=24(15 males,9 females); mean age=56(10) years; baseline sitting SBP=163(16) mm Hg, DBP=101(6) mm Hg;
Placebo: n=10(5 males,5 females); mean age=53(12) years; baseline SBP=157(14) mm Hg, DBP=100(7) mm Hg |
| Interventions |
Trandolapril 2 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer |
| Notes |
BP change and SD of change reported; endpoint BP and SD not reported; SBP/DBP data from Table 3, p. 110; Jadad score=3; funding source= Roussel Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
